While AI is taking off in biopharma for administrative tasks and drug discovery efforts, more than 90% of drugmakers have yet to commit to scaling AI use in regulated biopharma manufacturing, according to CRB’s new Horizons: Life Sciences report.

Original title: “Compliance concerns hinder rollout of AI in drug manufacturing: Survey”

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.

Original title: “The top biopharma conferences in 2027”

The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive drugs used in PET imaging.

Original title: “GE HealthCare to acquire Sofie Biosciences for $945M”

Collaboration aims to accelerate atrial fibrillation pipeline

Original title: “Quotient and Acesion partner on ai‑enhanced formulation”

Viking Therapeutics rode strong obesity data before a major capital raise, while Longeveron’s mid-stage setback prompted questions about its future.

Original title: “Significant stock movers of September: Viking soars, Longeveron slides”

Adecto Pharmaceuticals has ceased operations, while Aviceda Therapeutics is in the process of winding down.

Original title: “2 Massachusetts biotechs call it quits”

Eli Lilly first linked up with Gate Bioscience in July 2025 to leverage the biotech’s “Molecular Gate” engine to treat diseases with high unmet need. Monday’s expansion will add one undisclosed target to the existing agreement, with an option for a second.

Original title: “Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks”

CSL will co-develop and co-promote Alentis Therapeutics' anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune disease characterized by small blood vessel inflammation.

Original title: “CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential”

Why diagnostic-driven therapies need a new commercialization model to reach more eligible patients.

Original title: “Precision for All: Closing the gap between innovation and impact”

As AI accelerates drug discovery, here are the ways pharmaceutical manufacturing facilities are adapting.

Original title: “How AI is transforming biopharma manufacturing facilities of the future”